Literature DB >> 29769957

Canadian vaccine research networks: Vaccine safety resources for Canada.

J McCarthy1, S A Halperin1,2, J A Bettinger3,4, J M Langley1,2, N S Crowcroft5,6, S Deeks5,6, J C Kwong5,7, G De Serres8,9, K Top1,2, S McNeil1,10, D W Scheifele3.   

Abstract

The Public Health Agency of Canada / Canadian Institutes of Health Research Influenza Research Network (PCIRN), established in 2009 to undertake evaluative research to inform public health decision making in Canada, is now being replaced by the Canadian Immunization Research Network (CIRN), which will retain the mandate of PCIRN but expand it to all vaccines including influenza vaccine. CIRN is organized as a network of networks focusing on undertaking research in the areas of vaccine safety, adverse events following immunization (AEFIs), vaccine hesitancy, vaccine effectiveness, and vaccine coverage. CIRN's networks include: a clinical trial network; a laboratory network; a modelling and economics network; a network of social science and humanities researchers; a vaccine safety surveillance network; a hospital-based surveillance network; a clinic network to evaluate serious AEFIs; and a network that links vaccine research capacity in provincial health agencies and departments. PCIRN has contributed to Canada's vaccine safety surveillance system and has facilitated the translation of safety research into policy. Vaccine safety surveillance and research will remain a focus of the newly formed Canadian Immunization Research Network.

Year:  2015        PMID: 29769957      PMCID: PMC5868603          DOI: 10.14745/ccdr.v41is1a04

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  10 in total

1.  High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.

Authors:  Curtis Cooper; Marina Klein; Sharon Walmsley; David Haase; Donna MacKinnon-Cameron; Kimberley Marty; Yan Li; Bruce Smith; Scott Halperin; Barb Law; David Scheifele
Journal:  HIV Clin Trials       Date:  2012 Jan-Feb

2.  Rapid online identification of adverse events after influenza immunization in children by PCIRN's National Ambulatory Network.

Authors:  Julie A Bettinger; Otto G Vanderkooi; Judy MacDonald; James D Kellner
Journal:  Pediatr Infect Dis J       Date:  2014-10       Impact factor: 2.129

Review 3.  Egg-allergic patients can be safely vaccinated against influenza.

Authors:  Anne Des Roches; Louis Paradis; Remi Gagnon; Chantal Lemire; Philippe Bégin; Stuart Carr; Edmond S Chan; Jean Paradis; Lyne Frenette; Manale Ouakki; Mélanie Benoît; Gaston De Serres
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

4.  Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.

Authors:  Remi Gagnon; Marie Noel Primeau; Anne Des Roches; Chantal Lemire; Rhoda Kagan; Stuart Carr; Manale Ouakki; Mélanie Benoît; Gaston De Serres
Journal:  J Allergy Clin Immunol       Date:  2010-06-25       Impact factor: 10.793

5.  Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Authors:  Joanne M Langley; David W Scheifele; Caroline Quach; Otto G Vanderkooi; Brian Ward; Shelly McNeil; Simon Dobson; James D Kellner; Susan Kuhn; Tobias Kollman; Donna MacKinnon-Cameron; Bruce Smith; Yan Li; Scott A Halperin
Journal:  Vaccine       Date:  2012-03-30       Impact factor: 3.641

Review 6.  The Vaccine Safety Datalink: a model for monitoring immunization safety.

Authors:  James Baggs; Julianne Gee; Edwin Lewis; Gabrielle Fowler; Patti Benson; Tracy Lieu; Allison Naleway; Nicola P Klein; Roger Baxter; Edward Belongia; Jason Glanz; Simon J Hambidge; Steven J Jacobsen; Lisa Jackson; Jim Nordin; Eric Weintraub
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

7.  The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.

Authors:  Ethan Rubinstein; Gerald Predy; Laura Sauvé; Greg W Hammond; Fred Aoki; Chris Sikora; Yan Li; Barbara Law; Scott Halperin; David Scheifele
Journal:  CMAJ       Date:  2011-07-25       Impact factor: 8.262

8.  Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.

Authors:  David W Scheifele; Brian J Ward; Marc Dionne; Otto G Vanderkooi; Mark Loeb; Brenda L Coleman; Yan Li
Journal:  Vaccine       Date:  2012-05-28       Impact factor: 3.641

9.  Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine.

Authors:  Gaston De Serres; Marie-Claude Gariépy; Brenda Coleman; Isabelle Rouleau; Shelly McNeil; Mélanie Benoît; Allison McGeer; Ardith Ambrose; Judy Needham; Chantal Bergeron; Cynthia Grenier; Kenna Sleigh; Arlene Kallos; Manale Ouakki; Najwa Ouhoummane; Grant Stiver; Louis Valiquette; Anne McCarthy; Julie Bettinger
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

10.  Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.

Authors:  David W Scheifele; Marc Dionne; Brian J Ward; Curtis Cooper; Otto G Vanderkooi; Yan Li; Scott A Halperin
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

  10 in total
  1 in total

1.  Immunization in Canada: Update for 2015.

Authors:  Donna M MacDougall; Scott A Halperin
Journal:  J Can Chiropr Assoc       Date:  2016-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.